Prof. Michael Freissmuth
Dr. Freissmuth is the Director at the Centre of Physiology & Pharmacology as well as the Chairman of the Institute of Pharmacology at the Medical University in Vienna. He was appointed as Professor of Pharmacology in 1995 and has received many awards including the Novartis Award for Medicine. Dr. Freissmuth is a member of numerous editorial boards and serves on several review panels and Scientific Advisory Boards. His most recent appointments include positions in international panels such as the Scientific Advisory Board of the Institut Cochin de Génétique Moléculaire in Paris and of the Engelhorn Foundation for Life Sciences. He is also a member of the supervisory board of Boehringer Ingelheim Austria and chair of the reimbursement committee of the Association of Austrian Sickness Funds.
Prof. Dirk Jäger
Dr. Jäger is Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg and Medical Director of the Medical Oncology Department at Heidelberg University Hospital where he is responsible for the clinical research area representing all oncological departments. A main focus of his department is the translation of innovative treatment options into early clinical trials. Since 2005, Dr. Jäger is head of the research laboratory for tumor immunology at the NCT and focuses on cancer immunotherapy. He also leads the Clinical Cooperation Unit of Applied Tumor Immunity and has received the Investigator Award of the Cancer Research Institute in New York.
Prof. Florian Rüker
Dr. Florian Rüker is Associate Professor, Deputy Head of the Department of Biotechnology and Head of the Institute of Molecular Biotechnology at the University of Natural Resources and Life Sciences, Vienna (BOKU), encompassing a team of more than 230. He is a co-founder of F-star and co-inventor of F-star’s core Modular Antibody Technology, which allows to generate antigen binding sites in constant domains of immunoglobulins. Dr. Rüker serves F-star as Scientific Advisor. He also founded the Christian Doppler Laboratory (CD-Lab) for Antibody Engineering at BOKU where he acted as Co-head. Subsequently, he supported the establishment of the CD-Lab for Innovative Immunotherapeutics in collaboration with F-star and Merck KGaA, where he acts as Scientific Advisor.